Company Description
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH.
It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services.
argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
| Country | Netherlands |
| Founded | 2008 |
| IPO Date | May 18, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,148 |
| CEO | Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc. |
Contact Details
Address: Industriepark Zwijnaarde 7, Building C B-9052 Zwijnaarde, C9 B-9052 Belgium | |
| Phone | 32 (9) 310 34 00 |
| Website | argenx.com |
Stock Details
| Ticker Symbol | ARGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001697862 |
| CUSIP Number | 04016X101 |
| ISIN Number | US04016X1019 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc. | Chief Executive Officer and Executive Director |
| Karl Gubitz | Chief Financial Officer |
| Karen Massey | Chief Operating Officer |
| Filip Borgions | Vice President and Global Head of Technical Operations |
| Peter Ulrichts | Chief Scientific Officer |
| Beth DelGiacco | Vice President and Global Head of Corporate Communications and Investor Relations |
| Malini Moorthy | General Counsel |
| Arjen Lemmen M.Sc. | Vice President of Corporate Development and Strategy |
| Marc Schorpion | Global Head of Human Resources |
| Andria Wilk | Global Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 6-K | Report of foreign issuer |
| Mar 27, 2024 | 6-K | Report of foreign issuer |
| Mar 27, 2024 | 6-K | Report of foreign issuer |
| Mar 26, 2024 | 6-K | Report of foreign issuer |
| Mar 21, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 21, 2024 | 6-K | Report of foreign issuer |
| Mar 8, 2024 | 6-K | Report of foreign issuer |
| Feb 29, 2024 | 6-K | Report of foreign issuer |
| Feb 20, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |